Incretin-mimetic therapies and pancreatic disease: a review of observational data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incretin-mimetic therapies and pancreatic disease: a review of observational data

Published:2014-09-16 Issue:12 Volume:30 Page:2471-2481
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Suarez Elizabeth A.¹,Koro Carol E.²,Christian Jennifer B.³,Spector Alicia D.¹⁴,Araujo Andre B.¹⁵,Abraham Sybil⁶

Affiliation:

1. Department of Epidemiology, New England Research Institutes Inc. Watertown, MAUSA

2. Worldwide Epidemiology, GlaxoSmithKline Collegeville, PAUSA

3. Clinical Effectiveness and Safety, GlaxoSmithKline Research Triangle Park, NCUSA

4. PatientsLikeMe Cambridge, MAUSA (work completed while employed at New England Research Institutes)

5. Eli Lilly and Company Indianapolis, INUSA (work completed while employed at New England Research Institutes)

6. Global Clinical Safety and Pharmacovigilance GlaxoSmithKline, Collegeville, PAUSA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2014.960515

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials;Clinical Therapeutics;2024-08

2. The biological and pharmacological connections between diabetes and various types of cancer;Pathology - Research and Practice;2021-11

3. Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling;Molecular Cancer Research;2020-09-29

4. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus;Expert Opinion on Pharmacotherapy;2020-09-29

5. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system;BMC Pharmacology and Toxicology;2020-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3